IL6 and COVID-19: The effects of two important therapy methods, namely, the tocilizumab and convalescent plasma therapy (CPT) on IL-6 levels were also analyzed, which demonstrated that both methods were beneficial to patients with COVID-19, as indicated by a decrease in IL-6 levels.